Minerva Neurosciences Inc News
Minerva Shares Soar on Positive Schizophrenia Drug Trial
Minerva notes 'continuous improvement in negative symptoms' for users of roluperidone over one year in its Phase 3 trial.
Minerva Schizophrenia-Drug Trial Misses Key Endpoints
Roluperidone, a Minerva Neurosciences schizophrenia-drug candidate, failed to meet its key endpoints. But the company is undaunted.
Adamas Skyrockets on FDA Approval for Dyskinesia Treatment - Biotech Movers
The Emeryville, Calif.-based firm secures FDA approval for Gocovri as a treatment for dyskinesia in Parkinson's disease patients.
Biotech Premarket Movers: Esperion, Minerva and BioCryst
Esperion Therapeutics, Minerva Neurosciences and BioCryst Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.
Minerva Neurosciences (NERV) Stock Price Target Hiked at Jefferies
Minerva Neurosciences (NERV) stock price target was boosted at Jefferies earlier today following yesterday's positive results in two separate trials.
Minerva Neurosciences (NERV) Stock Skryockets on Positive Trial Results
Minerva Neurosciences (NERV) stock is soaring in early morning trading on Thursday following positive results in two separate trials.
Cisco Systems Stock Leaps On Q4 Earnings Beat, 2023 Sales Outlook As Supply Chain Pressures Ease
"Overall supply constraints began to ease slightly at the back half of the fourth quarter and continuing into the start of the first quarter," said CEO Chuck Robbins.
Apple Preparing For iPhone 14 Launch On September 7 - Report
Bloomberg reported late Wednesday that Apple is eyeing a September 7 launch date for its new iPhone 14 series.
Bed, Bath & Beyond Stock Dives As Ryan Cohen Moves to Sell Entire Stake
Ryan Cohen, who pushed for changes at Bed, Bath & Beyond including the ouster of CEO Mark Tritton, is looking to dump his entire 11.8% stake in the struggling home retailer.
Elon Musk Takes a Controversial Stand on Gender Equality
The richest man in the world sees himself as a global CEO, speaking his mind on just about anything.